Eye Drops Recalled Due to Improper Storage Violating Manufacturing Standards
Naphcon A eye drops are being recalled nationwide because products were stored outside label specifications, violating Current Good Manufacturing Practice (CGMP) standards.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves a CGMP deviation affecting storage conditions for a sterile ophthalmic drug. Although no illnesses or injuries have been reported, the manufacturing control failure and potential risk to product quality for a high-risk sterile product justify a High severity rating.
Plain-English summary
Naphcon A eye drops (containing Naphazoline HCl 0.025% and Pheniramine Maleate 0.3%) are being recalled nationwide. The product is manufactured by Alcon, a Novartis company, and distributed as sterile eye drops in 15 mL bottles to relieve redness and allergic reactions.
The FDA issued a Class II recall after determining that products were stored outside the conditions specified on the drug label. This storage deviation violates Current Good Manufacturing Practice (CGMP) standards.
The recalled product was distributed nationwide in the United States. The recall number is D-1313-2022. Consumers with questions or concerns should contact their healthcare provider or pharmacist.
The recalled product
- Product
- NAPHCON A (NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE)
- Brand
- NAPHCON A
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug — Ophthalmic
- Hazard
- improper-storage
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Part# 0065008515
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27